[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse TLR3

Summary
SymbolTLR3
Nametoll-like receptor 3
Aliases CD283; IIAE2; CD antigen CD283
Chromosomal Location4q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane; Single-pass type I membrane protein. Endosome membrane. Early endosome
Domain PF13516 Leucine Rich repeat
PF13855 Leucine rich repeat
PF01582 TIR domain
Function

Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. Acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response.

> Gene Ontology
 
Biological Process GO:0001774 microglial cell activation
GO:0001819 positive regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002281 macrophage activation involved in immune response
GO:0002282 microglial cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002367 cytokine production involved in immune response
GO:0002371 dendritic cell cytokine production
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002697 regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002730 regulation of dendritic cell cytokine production
GO:0002756 MyD88-independent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0002764 immune response-regulating signaling pathway
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0006970 response to osmotic stress
GO:0006972 hyperosmotic response
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007250 activation of NF-kappaB-inducing kinase activity
GO:0007252 I-kappaB phosphorylation
GO:0007254 JNK cascade
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0009597 detection of virus
GO:0009612 response to mechanical stimulus
GO:0009615 response to virus
GO:0017038 protein import
GO:0030099 myeloid cell differentiation
GO:0030316 osteoclast differentiation
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031349 positive regulation of defense response
GO:0031503 protein complex localization
GO:0032103 positive regulation of response to external stimulus
GO:0032147 activation of protein kinase activity
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032479 regulation of type I interferon production
GO:0032481 positive regulation of type I interferon production
GO:0032602 chemokine production
GO:0032606 type I interferon production
GO:0032607 interferon-alpha production
GO:0032608 interferon-beta production
GO:0032609 interferon-gamma production
GO:0032615 interleukin-12 production
GO:0032635 interleukin-6 production
GO:0032637 interleukin-8 production
GO:0032640 tumor necrosis factor production
GO:0032642 regulation of chemokine production
GO:0032647 regulation of interferon-alpha production
GO:0032648 regulation of interferon-beta production
GO:0032649 regulation of interferon-gamma production
GO:0032655 regulation of interleukin-12 production
GO:0032675 regulation of interleukin-6 production
GO:0032677 regulation of interleukin-8 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032722 positive regulation of chemokine production
GO:0032727 positive regulation of interferon-alpha production
GO:0032728 positive regulation of interferon-beta production
GO:0032729 positive regulation of interferon-gamma production
GO:0032735 positive regulation of interleukin-12 production
GO:0032755 positive regulation of interleukin-6 production
GO:0032757 positive regulation of interleukin-8 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032874 positive regulation of stress-activated MAPK cascade
GO:0033157 regulation of intracellular protein transport
GO:0033674 positive regulation of kinase activity
GO:0034121 regulation of toll-like receptor signaling pathway
GO:0034122 negative regulation of toll-like receptor signaling pathway
GO:0034123 positive regulation of toll-like receptor signaling pathway
GO:0034127 regulation of MyD88-independent toll-like receptor signaling pathway
GO:0034128 negative regulation of MyD88-independent toll-like receptor signaling pathway
GO:0034138 toll-like receptor 3 signaling pathway
GO:0034341 response to interferon-gamma
GO:0034343 type III interferon production
GO:0034344 regulation of type III interferon production
GO:0034346 positive regulation of type III interferon production
GO:0034504 protein localization to nucleus
GO:0035456 response to interferon-beta
GO:0035458 cellular response to interferon-beta
GO:0035666 TRIF-dependent toll-like receptor signaling pathway
GO:0035690 cellular response to drug
GO:0038061 NIK/NF-kappaB signaling
GO:0042033 chemokine biosynthetic process
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042095 interferon-gamma biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042116 macrophage activation
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042345 regulation of NF-kappaB import into nucleus
GO:0042346 positive regulation of NF-kappaB import into nucleus
GO:0042348 NF-kappaB import into nucleus
GO:0042493 response to drug
GO:0042742 defense response to bacterium
GO:0042990 regulation of transcription factor import into nucleus
GO:0042991 transcription factor import into nucleus
GO:0042993 positive regulation of transcription factor import into nucleus
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043330 response to exogenous dsRNA
GO:0043331 response to dsRNA
GO:0043410 positive regulation of MAPK cascade
GO:0044744 protein targeting to nucleus
GO:0045072 regulation of interferon-gamma biosynthetic process
GO:0045073 regulation of chemokine biosynthetic process
GO:0045078 positive regulation of interferon-gamma biosynthetic process
GO:0045080 positive regulation of chemokine biosynthetic process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045137 development of primary sexual characteristics
GO:0045349 interferon-alpha biosynthetic process
GO:0045350 interferon-beta biosynthetic process
GO:0045351 type I interferon biosynthetic process
GO:0045354 regulation of interferon-alpha biosynthetic process
GO:0045356 positive regulation of interferon-alpha biosynthetic process
GO:0045357 regulation of interferon-beta biosynthetic process
GO:0045359 positive regulation of interferon-beta biosynthetic process
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045671 negative regulation of osteoclast differentiation
GO:0045860 positive regulation of protein kinase activity
GO:0046328 regulation of JNK cascade
GO:0046330 positive regulation of JNK cascade
GO:0046546 development of primary male sexual characteristics
GO:0046661 male sex differentiation
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0048608 reproductive structure development
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050755 chemokine metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0051403 stress-activated MAPK cascade
GO:0051607 defense response to virus
GO:0061458 reproductive system development
GO:0070265 necrotic cell death
GO:0070266 necroptotic process
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070304 positive regulation of stress-activated protein kinase signaling cascade
GO:0071214 cellular response to abiotic stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071346 cellular response to interferon-gamma
GO:0071359 cellular response to dsRNA
GO:0071360 cellular response to exogenous dsRNA
GO:0071407 cellular response to organic cyclic compound
GO:0071496 cellular response to external stimulus
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0090316 positive regulation of intracellular protein transport
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097300 programmed necrotic cell death
GO:0097527 necroptotic signaling pathway
GO:0098542 defense response to other organism
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1901222 regulation of NIK/NF-kappaB signaling
GO:1901224 positive regulation of NIK/NF-kappaB signaling
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902593 single-organism nuclear import
GO:1903533 regulation of protein targeting
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0003725 double-stranded RNA binding
Cellular Component GO:0005765 lysosomal membrane
GO:0005769 early endosome
GO:0010008 endosome membrane
GO:0036019 endolysosome
GO:0036020 endolysosome membrane
GO:0044440 endosomal part
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04620 Toll-like receptor signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-936964: Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
R-HSA-109581: Apoptosis
R-HSA-5357769: Caspase activation via extrinsic apoptotic signalling pathway
R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-1643685: Disease
R-HSA-5602358: Diseases associated with the TLR signaling cascade
R-HSA-5260271: Diseases of Immune System
R-HSA-937041: IKK complex recruitment mediated by RIP1
R-HSA-975163: IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-140534: Ligand-dependent caspase activation
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-5357801: Programmed Cell Death
R-HSA-1810476: RIP-mediated NFkB activation via ZBP1
R-HSA-5602566: TICAM1 deficiency - HSE
R-HSA-5602410: TLR3 deficiency - HSE
R-HSA-5602571: TRAF3 deficiency - HSE
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937072: TRAF6 mediated induction of TAK1 complex
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-2562578: TRIF-mediated programmed cell death
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-1679131: Trafficking and processing of endosomal TLR
R-HSA-5602415: UNC93B1 deficiency - HSE
R-HSA-1606322: ZBP1(DAI) mediated induction of type I IFNs
Summary
SymbolTLR3
Nametoll-like receptor 3
Aliases CD283; IIAE2; CD antigen CD283
Chromosomal Location4q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TLR3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TLR3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25646304Melanoma; Pancreatic Carcinoma; Prostate CarcinomaPromote immunityThe combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.
29324304MelanomaPromote immunity (T cell function); essential for immunotherapyInjectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma.
23197495Hepatocellular carcinomaPromote immunityTLR3 activation increased cell death in the TLR3(+) SNU182 HCC cell line (30.5% vs 8.5%, P = .03) and promoted NK-cell activation (32.6% vs 19.4%, P < .001) and cytotoxicity (relative fourfold increase, P = .03) in vitro.
19299748Plasma cell myelomaPromote immunityIn conclusion, our results show that TLR3 ligand induces NF-kappaB pathway activation in MM and support a switching function of type I IFN in the functional outcome of TLR3 triggering in tumor cells.
23520337Leukemia; LymphomaPromote immunityStimulation of TLR3, which among host hematopoietic APC subsets is predominantly expressed on CD8(+) DCs, enhanced GVT without exacerbating GVHD.
19887600Pancreatic CarcinomaPromote immunity (T cell function)Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Poly(I:C) treatment of pancreatic adenocarcinomas followed by coculture with gammadelta T cells resulted in an upregulation of CD54 on the tumor cells. The interaction of CD54 and the corresponding ligand CD11a/CD18 expressed on gammadelta T cells is responsible for triggering effector function in gammadelta T cells.
19201856MelanomaPromote immunity (T cell function)In vivo, administration of the TLR3 agonist poly(I:C) at the peak of DC expansion (day 12 postlymphopenia) induced inflammatory cytokine production and increases in the number of activated DCs in lymph nodes.
29669207melanomaPromote immunity (T cell function); essential for immunotherapyROS-Inducing Micelles Sensitize Tumor-Associated Macrophages to TLR3 Stimulation for Potent Immunotherapy.
21421234Bladder CarcinomaPromote immunity (T cell function & infiltration); essential for immunotherapyTreatment with toll-like receptor 2 and 3 agonists showed the strongest inflammatory response in 2 primary cultures of normal urothelial cells and 3 bladder cancer cell lines. In cultured urothelial cells agonist inducible toll-like receptor 2 or constitutively expressed toll-like receptor 3 is functional. These data suggest the potential use of toll-like receptor agonists for antitumor immunotherapy of nonmuscle invasive tumors.
24321786Lung CarcinomaPromote immunityHere we show that autophagy induced by TLR4 or TLR3 activation enhances various cytokine productions through promoting TRAF6 (TNF receptor-associated factor 6, E3 ubiquitin protein ligase) ubiquitination and thus facilitates migration and invasion of lung cancer cells. Remarkably, inhibition of autophagy by chemical or genetic approaches blocked TLR4- or TLR3-induced Lys63 (K63)-linked ubiquitination of TRAF6 that was essential for activation of MAPK and NFKB (nuclear factor of kappa light polypeptide gene enhancer in B-cells) pathways, both of which were involved in the increased production of the cytokines.
22058147Head and Neck Squamous Cell CarcinomaPromote immunityEnhanced apoptosis in metastatic cells was dependent on double-stranded RNA and TLR3 and also the TLR3 effector signaling protein TRIF.
20483744Prostate CarcinomaPromote immunityOverall, these data show for the first time that TLR3 and TLR5 stimulation of human prostate cancer cells triggers the production of chemokines, which, in turn, favor the attraction of immune effectors, thereby representing a tool to enhance the efficacy of conventional therapies by stimulating anticancer immune responses.
20233880Prostate CarcinomaPromote immunityIn our study, we implicate TLR3 in mediating immune surveillance with increased growth of implanted transgenic adenocarcinoma of the mouse prostate (TRAMP) tumors in TLR3(-/-) compared with TLR3(+/+) mice. Activation of TLR3 by polyinosinic-polycytidylic acid (polyI:C) leads to induction of multiple inflammatory pathways, including NF-kappaB, mitogen-activated protein kinases, and interferon (IFN) regulatory factors.
29755681GlioblastomaPromote immunity; Essential for immunotherapyWe show that activating DCs through TLR3 agonists enhances the anti-tumor immune response to CB and increases survival in GBM. Mice treated with TLR3 agonist poly(I:C) and anti-PD-1 demonstrated increased DC activation and increased T cell proliferation in tumor draining lymph nodes.
29721392Hepatocellular CarcinomaPromote immunityIn consistent with previous reports, we found that poly (I:C) triggering of TLR3 inhibited cell proliferation and induced apoptosis in HCC cells.
Summary
SymbolTLR3
Nametoll-like receptor 3
Aliases CD283; IIAE2; CD antigen CD283
Chromosomal Location4q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TLR3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTLR3
Nametoll-like receptor 3
Aliases CD283; IIAE2; CD antigen CD283
Chromosomal Location4q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TLR3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5250.203
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5320.565
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5280.425
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3260.482
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3970.803
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2490.882
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1170.781
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5940.534
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5470.649
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3460.749
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5160.773
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.020.894
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TLR3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTLR3
Nametoll-like receptor 3
Aliases CD283; IIAE2; CD antigen CD283
Chromosomal Location4q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TLR3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTLR3
Nametoll-like receptor 3
Aliases CD283; IIAE2; CD antigen CD283
Chromosomal Location4q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TLR3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TLR3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTLR3
Nametoll-like receptor 3
Aliases CD283; IIAE2; CD antigen CD283
Chromosomal Location4q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TLR3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTLR3
Nametoll-like receptor 3
Aliases CD283; IIAE2; CD antigen CD283
Chromosomal Location4q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TLR3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTLR3
Nametoll-like receptor 3
Aliases CD283; IIAE2; CD antigen CD283
Chromosomal Location4q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TLR3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTLR3
Nametoll-like receptor 3
Aliases CD283; IIAE2; CD antigen CD283
Chromosomal Location4q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TLR3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.